A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Rabbit ATG in the Prophylaxis of Acute Rejection in Lung Transplantation Academic Article uri icon

  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All


  • ATG-Fresenius S (ATG-F) is a polyclonal anti-human-T-lymphocyte immunoglobulin preparation that has been clinically developed to prevent episodes of acute cellular rejection. This study evaluated the efficacy and safety of ATG-F at doses of 5 and 9 mg/kg versus placebo in adult recipients of a primary lung allograft. The primary efficacy composite end point was defined as death, graft loss, acute rejection and/or loss to follow-up within 12 months of transplantation. The interim analysis showed the ATG-F 5 mg/kg treatment to be inefficacious, and it would be impossible to enroll enough patients to power the study to show a difference between the 9 mg/kg arm and the placebo arm. Therefore, the main focus of the study shifted to the safety end points and a descriptive analysis of the primary end point. At 12 months posttransplant, the efficacy failure rate was not significantly different between the ATG-F 9 mg/kg group and the placebo group (40.2% vs. 36.7%, respectively). This large study did not demonstrate a significant reduction in acute cellular rejection, graft loss or death with single-dose induction therapy with ATG-F within the first year after lung transplantation.


  • Snell, GI
  • Westall, GP
  • Levvey, BJ
  • Jaksch, P
  • Keshavjee, Shafique
  • Hoopes, CW
  • Ahya, V
  • Mehta, A
  • Trulock, EP

publication date

  • May 2014